- Home
- PSNYW vs MYGN Comparison
PSNYW vs MYGN Comparison
Compare PSNYW & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNYW
- MYGN
- Stock Information
- Founded
- PSNYW 2017
- MYGN 1991
- Country
- PSNYW Sweden
- MYGN United States
- Employees
- PSNYW 2547
- MYGN 2700
- Industry
- PSNYW Auto Manufacturing
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- PSNYW Consumer Discretionary
- MYGN Health Care
- Exchange
- PSNYW Nasdaq
- MYGN Nasdaq
- Market Cap
- PSNYW 625.2M
- MYGN 756.5M
- IPO Year
- PSNYW N/A
- MYGN 1995
- Fundamental
- Price
- PSNYW $0.26
- MYGN $7.91
- Analyst Decision
- PSNYW
- MYGN Hold
- Analyst Count
- PSNYW 0
- MYGN 13
- Target Price
- PSNYW N/A
- MYGN $13.50
- AVG Volume (30 Days)
- PSNYW 43.4K
- MYGN 898.4K
- Earning Date
- PSNYW 03-06-2025
- MYGN 11-03-2025
- Dividend Yield
- PSNYW N/A
- MYGN N/A
- EPS Growth
- PSNYW N/A
- MYGN N/A
- EPS
- PSNYW N/A
- MYGN N/A
- Revenue
- PSNYW $2,034,261,000.00
- MYGN $832,900,000.00
- Revenue This Year
- PSNYW N/A
- MYGN $0.06
- Revenue Next Year
- PSNYW $79.49
- MYGN $5.68
- P/E Ratio
- PSNYW N/A
- MYGN N/A
- Revenue Growth
- PSNYW N/A
- MYGN 3.83
- 52 Week Low
- PSNYW $0.09
- MYGN $3.76
- 52 Week High
- PSNYW $0.61
- MYGN $22.92
- Technical
- Relative Strength Index (RSI)
- PSNYW 50.45
- MYGN 54.58
- Support Level
- PSNYW $0.23
- MYGN $7.68
- Resistance Level
- PSNYW $0.30
- MYGN $8.50
- Average True Range (ATR)
- PSNYW 0.04
- MYGN 0.38
- MACD
- PSNYW 0.00
- MYGN -0.03
- Stochastic Oscillator
- PSNYW 24.34
- MYGN 45.60
About PSNYW Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)
Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars, namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from the United Kingdom.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.